<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04423757</url>
  </required_header>
  <id_info>
    <org_study_id>1402-0014</org_study_id>
    <nct_id>NCT04423757</nct_id>
  </id_info>
  <brief_title>A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression</brief_title>
  <official_title>A Phase II 6-week, Randomized, Double-blinded, Placebocontrolled, Parallel Group Decentralised Clinical Trial to Evaluate Efficacy and Safety of Oral BI 1358894 in Patients With Major Depressive Disorder With Inadequate Response to Antidepressants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of this trial are to evaluate the efficacy and safety of oral BI 1358894
      compared to placebo over a 6-week treatment period in participants with Major Depressive
      Disorder (MDD) and with inadequate response to antidepressants (SSRI or SNRI) utilizing a
      decentralized clinical trial (DCT) model.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score</measure>
    <time_frame>At week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS), response defined as ≥ 50% MADRS reduction from baseline</measure>
    <time_frame>At week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State-Trait Anxiety Inventory (STAI), change from baseline in STAI State and Trait version scores</measure>
    <time_frame>At week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Severity Scale (CGI-S), change from baseline in CGI-S score</measure>
    <time_frame>At week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of Major Depressive Disorder Scale (SMDDS), change from baseline in SMDDS total score</measure>
    <time_frame>At week 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>BI 1358894</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1358894</intervention_name>
    <description>BI 1358894</description>
    <arm_group_label>BI 1358894</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of Major Depressive Disorder, single episode or recurrent, as
             confirmed at the time of screening by the Structured Clinical Interview for Diagnostic
             and Statistical Manual of Mental Disorders v5 (DSM-5, SCID-5), with a duration of
             current depressive episode ≥ 8 weeks and ≤ 12 months at the time of screening visit.

          -  Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥ 22 at screening, as
             confirmed by a trained rater. In addition, trial participants must have a score of ≥ 3
             on item number 2 on MADRS.

          -  A documented ongoing monotherapy treatment of ≥ 8 weeks at the screening visit, with a
             protocol specified SSRI or SNRI (refer to the ISF) at adequate dose (at least minimum
             effective dose as per prescribing information and as confirmed per detectable drug
             levels in the screening blood sampling).

          -  Male and female participants, 18 to 65 years of age, both inclusively at the time of
             consent.

          -  Women of child-bearing potential (WOCBP)2 able and willing to use two methods of
             contraception, which include one highly effective method of birth control per ICH M3
             (R2) that results in a low failure rate of less than 1%, plus one barrier method.

          -  Signed and dated written informed consent in accordance with ICH-GCP and local
             legislation prior to admission to the trial.

          -  Able to communicate well, and to understand and comply with trial requirements.

        Exclusion Criteria:

          -  Per DSM-5, had ever met diagnostic criteria for schizophrenia, schizoaffective
             disorder, schizophreniform disorder, bipolar disorder, delusional disorder or MDD with
             psychotic features as assessed by the Structured Clinical Interview for DSM ‐5
             (SCID-5) at the time of screening.

          -  Diagnosis of any other mental disorder (in addition to those as described in Exclusion
             Criterion #1) that was the primary focus of treatment within 6 months prior to
             screening or at baseline (as per clinical discretion of the investigator).

          -  Diagnosis with antisocial, paranoid, schizoid or schizotypal personality disorder as
             per DSM-5 criteria, at the time of screening visit. Any other personality disorder at
             screening visit that significantly affects current psychiatric status and likely to
             impact trial participation, as per the judgement of investigator.

          -  Diagnosis of a substance related disorder within 3 months prior to screening visit
             (with exception of caffeine and tobacco).

          -  History of seizure disorders, stroke, brain tumor or any other major neurological
             illness that can impact participation in the trial.

          -  History of more than 2 unsuccessful monotherapy treatments (at adequate dosage and
             duration, per local prescribing information of the product) with an approved
             antidepressant medication for the current ongoing major depressive episode. These
             include ongoing monotherapy treatment with a protocol specified SSRI or SNRI as
             described in Inclusion Criterion #3.

          -  Any suicidal behavior in the past 12 months prior to screening (per investigator
             judgement including an actual attempt, interrupted attempt, aborted attempt, or
             preparatory acts or behaviour).

          -  Any suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale
             (CSSRS) in the past 3 months prior to screening or at screening or baseline visit
             (i.e. active suicidal thought with method and intent but without specific plan, or
             active suicidal thought with method, intent and plan).

          -  Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Science 37, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Reist</last_name>
      <phone>+001 (562) 760-6041</phone>
      <email>chris.reist@science37.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://trials.boehringer‐ingelheim.com/trial_results/clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.
Also, Researchers can use the following link http://trials.boehringer‐ingelheim.com/ to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://trials.boehringer‐ingelheim.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

